Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Randomized Clinical Trial of a new Anti–Cervical Stenosis Device after Conization by Loop Electrosurgical Excision v1

View through CrossRef
Background: The complications inherent to conization include vaginal bleeding, cervical stenosis, amenorrhea, dysmenorrhea, and deep dyspareunia. Cervical stenosis is the most critical complication due to clinical repercussions. Studies show rates of cervical stenosis ranging from 1.3 to 19% after LEEP. Objective: Randomized controlled trial (RCT) data is need comparing the use of a new anti-stenosis cervical device in the treatment of cervical precursor lesions. Our primary outcome was to compare the role of a new endocervical device to prevent cervical stenosis after LEEP in patients with high-grade squamous intraepithelial lesions (HSILs) by the conduct of a randomized clinical trial. Study design: According to the standards of randomized clinical trials, we performed phases I and II on the new cervical device. In Phase I, we included 25 patients who underwent conization and placement of the device to assess its toxicity. In phase II, we compared two groups (with and without the use of an anti-stenosis device) to evaluate its efficacy and safety. Results: From August 2015 to June 2018, 265 participants were randomized (Phase I: 25, Phase II: 120 with DUDA ́s device and 120 without DUDA ́s device). The toxicity during phase I was observed in only one patient (4%) with pain grade > 7. There were 7 cases of toxicity during Phase II, 2 in the DUDA group (1.8%), and 5 in the No DUDA group (4.5%). The No DUDA group had a 2.5x higher complication rate than the DUDA group (p=0.52). When comparing the evolution at 3, 6, and 12 months in terms of cervical patency and visualization of the squamocolumnar junction (SCJ) during colposcopy, we did not find a significant difference. The DUDA group exhibited 15% to 19% nonvisualization of the SCJ, whereas that rate ranged from 10 to 12% in the No DUDA group. Conclusions: There was no statistically significant difference between the use or non- use of the antistenosis device to prevent cervical stenosis. This study opens up space for a discussion of cervical stenosis related to the type of conization performed and the use of antistenosis devices to help lower the stenosis rate.
Title: Randomized Clinical Trial of a new Anti–Cervical Stenosis Device after Conization by Loop Electrosurgical Excision v1
Description:
Background: The complications inherent to conization include vaginal bleeding, cervical stenosis, amenorrhea, dysmenorrhea, and deep dyspareunia.
Cervical stenosis is the most critical complication due to clinical repercussions.
Studies show rates of cervical stenosis ranging from 1.
3 to 19% after LEEP.
Objective: Randomized controlled trial (RCT) data is need comparing the use of a new anti-stenosis cervical device in the treatment of cervical precursor lesions.
Our primary outcome was to compare the role of a new endocervical device to prevent cervical stenosis after LEEP in patients with high-grade squamous intraepithelial lesions (HSILs) by the conduct of a randomized clinical trial.
Study design: According to the standards of randomized clinical trials, we performed phases I and II on the new cervical device.
In Phase I, we included 25 patients who underwent conization and placement of the device to assess its toxicity.
In phase II, we compared two groups (with and without the use of an anti-stenosis device) to evaluate its efficacy and safety.
Results: From August 2015 to June 2018, 265 participants were randomized (Phase I: 25, Phase II: 120 with DUDA ́s device and 120 without DUDA ́s device).
The toxicity during phase I was observed in only one patient (4%) with pain grade > 7.
There were 7 cases of toxicity during Phase II, 2 in the DUDA group (1.
8%), and 5 in the No DUDA group (4.
5%).
The No DUDA group had a 2.
5x higher complication rate than the DUDA group (p=0.
52).
When comparing the evolution at 3, 6, and 12 months in terms of cervical patency and visualization of the squamocolumnar junction (SCJ) during colposcopy, we did not find a significant difference.
The DUDA group exhibited 15% to 19% nonvisualization of the SCJ, whereas that rate ranged from 10 to 12% in the No DUDA group.
Conclusions: There was no statistically significant difference between the use or non- use of the antistenosis device to prevent cervical stenosis.
This study opens up space for a discussion of cervical stenosis related to the type of conization performed and the use of antistenosis devices to help lower the stenosis rate.

Related Results

Prevention of Cervical Stenosis After Cervical Conization Using a Nelaton Catheter: A Retrospective Analysis of 556 Cases
Prevention of Cervical Stenosis After Cervical Conization Using a Nelaton Catheter: A Retrospective Analysis of 556 Cases
Objective: This study aimed to investigate 1) the incidence of and risk factors for cervical stenosis, and 2) the ability of prophylactic catheter insertion to prevent the cervical...
THE ROLE OF MAGNETIC RESONANCE IMAGING IN THE DIAGNOSIS AND TREATMENT ORIENTATION OF CERVICAL SPINAL STENOSIS SYNDROMES
THE ROLE OF MAGNETIC RESONANCE IMAGING IN THE DIAGNOSIS AND TREATMENT ORIENTATION OF CERVICAL SPINAL STENOSIS SYNDROMES
Objectives: To study on the magnetic resonance imaging (MRI) to diagnose the causes of cervical spinal stenosis and contribution to therapeutic orientations in cervical spinal sten...
Atypical Presentations of Pilonidal Sinus Disease: A Case Series with Literature Review
Atypical Presentations of Pilonidal Sinus Disease: A Case Series with Literature Review
Abstract Introduction: Pilonidal sinus (PNS) typically arises in the sacrococcygeal region but can occasionally present in atypical locations, including the axilla, intermammary re...
Adjuvant VaccInation After Conization for the Treatment for CervicAL Dysplasia
Adjuvant VaccInation After Conization for the Treatment for CervicAL Dysplasia
This study aimed to evaluate the role of adjuvant HPV vaccination in women undergoing conization for cervical intraepithelial neoplasia. This prospective study assessed factors inf...
The Burden of Cervical Conization in Privately Insured Young and Mid-Adult Women in the United States
The Burden of Cervical Conization in Privately Insured Young and Mid-Adult Women in the United States
In 2019, the United States (US) Advisory Committee on Immunization Practices (ACIP) recommended that healthcare providers engage in shared clinical decision making for adults aged ...
Presentation and Management of Cervical Thoracic Duct Cyst: A Systematic Review of the Literature
Presentation and Management of Cervical Thoracic Duct Cyst: A Systematic Review of the Literature
Abstract Introduction Thoracic duct cysts are an uncommon phenomenon, especially within the cervical region. Due to its limited reported cases, very little is known about its etiol...
Rare Complication Post-Conization for Cervical Dysplasia: Rectovaginal Fistula
Rare Complication Post-Conization for Cervical Dysplasia: Rectovaginal Fistula
(1) Background: High-grade cervical dysplasia is primarily caused by human papillomavirus (HPV) infection. Conservative surgery is the preferred treatment approach for this conditi...
Is “additional cut” effective for positive margin in cervical conization? It varies with doctors: a retrospective study
Is “additional cut” effective for positive margin in cervical conization? It varies with doctors: a retrospective study
Objective: We aimed at discussing additional cuts, a common problem in cervical conization. Whether the doctor’s choice of additional cuts in conization surgery could reduce the oc...

Back to Top